Toki H
Acta Med Okayama. 1976 Apr;30(2):135-42.
Neocarzinostain (NCS) was first used by Hiraki and his colleagues for induction chemotherapy in acute leukemia. This new anti-tumor agent is a polypeptide with a high molecular weight of 10,700 daltons. Anti-NCS antibody was produced in rabbits administered NCS intramuscularly with or without adjuvant. The production of anti-NCS antibody in patients treated with NCS was investigated. Forty three leukemia cases of various types were examined totally 65 times. Two mg of NCS for four consecutive days by intravenous drip infusion followed by 7 to 10 days of pause was repeatedly administered. The total amounts ranged 8 to 174 mg and the total periods 4 to 87 days. The methods used to measure the antibody titer are the passive hemagglutination (PHA) test on microplate and the passive cutaneous anaphylaxis (PCA) reaction in guinea pigs. The sera of all patients showed only non-specific agglutination at less than 2(3) dilution by PHA test, and to confirm these results four patient sera were tested by PCA reaction. The production of anti-NCS antibody was not detected in patients by PHA test and PCA reaction. The anaphylactic reaction and other adverse reactions due to anti-NCS adtibody production were not demonstrated in patients. Anti-NCS antibody was not detected by these experiments in the dose schedule administered.
新制癌菌素（NCS）最早由平木及其同事用于急性白血病的诱导化疗。这种新型抗肿瘤药物是一种分子量为10700道尔顿的多肽。通过对兔肌肉注射NCS（有无佐剂）制备抗NCS抗体。对接受NCS治疗的患者体内抗NCS抗体的产生情况进行了研究。共检查了43例不同类型的白血病病例，总计65次。连续4天静脉滴注2毫克NCS，随后暂停7至10天，重复给药。总量为8至174毫克，总疗程为4至87天。用于测量抗体滴度的方法是微孔板上的被动血凝（PHA）试验和豚鼠的被动皮肤过敏反应（PCA）。所有患者的血清在PHA试验中稀释度小于2(3)时仅显示非特异性凝集，为证实这些结果，对4例患者血清进行了PCA反应检测。通过PHA试验和PCA反应未在患者中检测到抗NCS抗体的产生。在患者中未显示出因抗NCS抗体产生而导致的过敏反应和其他不良反应。在所用给药方案中，通过这些实验未检测到抗NCS抗体。
